Sevion Therapeutics Inc (OTCBB - OTCQB:SVON)

0.635
Delayed Data
As of Mar 27
 +0.005 / +0.79%
Today’s Change
0.51
Today|||52-Week Range
3.69
-22.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$8.8M

Company Description

Sevion Therapeutics, Inc. is a development stage company, which develops cancer therapeutics products. It has developed eukaryotic translation initiation Factor 5A technology to regulate cell death and survival. The company focuses on portfolio with other potential eukaryotic translation initiation Factor 5A applications in cancer, inflammation and ischemia. It has developed therapeutic candidate, SNS01-T for the potential treatment of multiple myeloma. The company was founded on September 30, 1999 and is headquartered in Bridgewater, NJ.

Contact Information

Sevion Therapeutics, Inc.
721 Route 202/206
Bridgewater New Jersey 08807-1760
P:(908) 864-4444
Investor Relations:

Employees

Shareholders

Individual stakeholders20.83%
Mutual fund holders--
Other institutional--

Top Executives

David S. RectorPresident & Chief Executive Officer
James Joseph GrazianoChief Technology Officer
Vaughn V. SmiderDirector & Chief Scientific Officer
Miguel A. de los RíosVice President-Research
Alice S. BexonVice President-Clinical Development

To view my watchlist

Not a member yet?

Sign up now for a free account